secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-06-02T21:10:31+00:00
Accession:  0001213900-26-064278
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity amends CEO Thomas Jensen's management agreement; increases severance, alters pay structure
--------------------------------------------------------------------------------

- Base compensation set at SEK 6,000,000 (80%) and US$163,043 (20%) annually; eliminates $100,000 signing bonus.
- Termination for convenience: notice period increased from 15 to 30 days; now includes 12 months of Monthly Fee as severance.
- Termination for Good Reason: now entitles consultant to Accrued Payments plus 12 months of Monthly Fee (replaces prior 9 months).
- Annual bonus capped at 60% of Monthly Fees; performance metrics carry over if not updated by March 31 each year.
- Adds Section 409A and 280G tax compliance provisions; extends non-solicitation period to 12 months post-termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026064278/0001213900-26-064278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026064278/ea0293097-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-064278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer